India, March 17 -- Shares of Precision BioSciences, Inc. (DTIL) were gaining around 11 percent in pre-market activity on the Nasdaq after the clinical-stage gene editing company on Monday announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug or IND application for PBGENE-HBV to eliminate root cause of chronic hepatitis B.
With no curative options currently available for patients, Hepatitis B is a leading cause of morbidity in the US and death globally. PBGENE-HBV is Precision's lead wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial. It is designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replicating hepatitis B virus or...